Literature DB >> 12065693

Molecular mechanisms for heterologous sensitization of adenylate cyclase.

Val J Watts1.   

Abstract

The nine membrane-bound isoforms of the enzyme adenylate cyclase (EC 4.6.1.1) are highly regulated by neurotransmitters and drugs acting through G protein-coupled receptors to modulate intracellular cAMP levels. In general, acute activation of Galpha(s)-coupled receptors stimulates cAMP accumulation, whereas acute activation of Galpha(i/o)-coupled receptors typically inhibits cAMP accumulation. It is also well established that persistent activation of G-protein coupled receptors will alter subsequent drug-modulated cAMP accumulation. These alterations are thought to represent cellular adaptive responses following prolonged receptor activation. One phenomenon commonly observed, heterologous sensitization of adenylate cyclase, is characterized by an enhanced responsiveness to drug-stimulated cAMP accumulation following persistent activation of Galpha(i/o)-coupled receptors. Heterologous sensitization of adenylate cyclase was originally proposed to explain tolerance and withdrawal following chronic opiate administration and may be a mechanism by which cells adapt to prolonged activation of inhibitory receptors. Such an adaptive mechanism has been suggested to play a role in the processes of addiction to and withdrawal from many drugs of abuse and in psychiatric disorders including schizophrenia and depression. Although the precise mechanisms remain unknown, research over the last decade has led to advances toward understanding the molecular events associated with heterologous sensitization of recombinant and endogenous adenylate cyclases in cellular models. These events include the pertussis toxin-sensitive events that are associated with the development of heterologous sensitization and the more recently identified Galpha(s)-dependent events that are involved in the expression of heterologous sensitization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065693     DOI: 10.1124/jpet.302.1.1

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  32 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

4.  cAMP response element binding protein phosphorylation in nucleus accumbens underlies sustained recovery of sensorimotor gating following repeated D₂-like receptor agonist treatment in rats.

Authors:  Alison K Berger; Thomas Green; Steven J Siegel; Eric J Nestler; Ronald P Hammer
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

5.  Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters.

Authors:  Julia A Chester; Amanda J Mullins; Chau H Nguyen; Val J Watts; Robert L Meisel
Journal:  Psychopharmacology (Berl)       Date:  2006-07-19       Impact factor: 4.530

6.  Inhibition of AC-II activity following chronic agonist exposure is modulated by phosphorylation.

Authors:  Ester Schallmach; Debora Steiner; Zvi Vogel
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.

Authors:  Erica S Levitt; Lauren C Purington; John R Traynor
Journal:  Mol Pharmacol       Date:  2010-11-22       Impact factor: 4.436

8.  Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Authors:  Tarsis F Brust; Michael P Hayes; David L Roman; Kevin D Burris; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2014-12-24       Impact factor: 4.030

Review 9.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

10.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.